Boston firm No. 3 on Deloitte Technology Fast 500

BOSTON – Boston-based Toast Inc. made No. 3 on the Deloitte 2017 North America Technology Fast 500 winners list, the annual roundup of the fastest-growing tech companies in the nation. The software company showed 31,250 percent fiscal-year revenue growth from 2013-2016, according to Deloitte.

Though no Rhode Island companies made the list this year, there were 31 from Massachusetts in addition to Toast, and two from Connecticut.

Other Massachusetts firms that made the list include: Eleven Biotherapeutics; Convergent Dental; T2 Biosystems Inc.; Maxwell Health; Ironwood Pharmaceuticals; QStream; Ziopharm Oncology; Definitive Healthcare; Viral Gains; Agenus Inc.; Proteostasis Therapeutics; TraceLink; AMAG Pharmaceuticals Inc.; Acacia Communications; Onapsis; Keryx Biopharmaceuticals; Recorded Future; Fuse: Hubspot; Buildium; Corindus Vascular Robotics; Momenta Pharmaceuticals; Merrimack Pharmaceuticals; Perfecto; Applause; Enanta Pharmaceuticals; Everquote; Everbridge Inc.; ownerIQ; Fusion Optix; and Semcasting.

Connecticut companies in the 500 were software firms Evariant, based in Farmington, and etouches, of Norwalk.

- Advertisement -

The 500 ranked companies for 2017 achieved revenue growth ranging from 135 percent to 59,093 percent during the 2013-2016 time period; median growth was 380 percent, according to Deloitte.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world-class customer service in driving growth, in a fiercely competitive environment. These companies are on the cutting edge and are transforming the way we do business,” said Sandra Shirai, Deloitte’s U.S. technology, media and telecommunications leader.

Overall, 17 of the top 20 growing tech firms on the list are privately owned, according to Deloitte. Software emerged as a leading national market, with 293 companies on the list. Biotechnology/pharmaceuticals saw a 4 percent increase in overall growth compared to last year.

Susan Shalhoub is a PBN contributor.